Access to Hep C Treatment in Texas Medicaid Delayed
By Emma Freer

Texas Medicaid patients with hepatitis C will have to wait a little longer to access potentially curative antiviral medications.  

The Texas Health and Human Services Commissions (HHSC) has delayed until Jan. 1 a prescription drug formulary update that was originally scheduled to take effect Sept. 1.

Starting next year, Texas Medicaid will designate a preferred direct-acting antiviral drug option for treating hepatitis C, responding to advocacy by the Texas Medical Association and others in organized medicine to expand patient access to the drug. 

An HHSC spokesperson attributed the delay to a longer-than-expected procurement process for the hepatitis C preferred drug rebate program.  

Per federal rules, if pharmaceutical companies want Medicaid to cover their products, they must agree to pay rebates to state programs to offset the drug costs. Texas, along with a handful of other states, requires companies to pay additional, or supplemental, rebates to be considered a preferred drug. 

Last Updated On

September 07, 2022

Originally Published On

September 07, 2022

Related Content

Infectious Diseases | Medicaid

Emma Freer


(512) 370-1383

Emma Freer is a reporter for Texas Medicine. She previously worked in local news, covering city politics, economic development, and public health. A native Clevelander, she graduated from Columbia Journalism School and the University of St. Andrews.

More stories by Emma Freer